Drug intelligence / Profile preview

Simbrinza

Development stage: Approved
Lead developer: Alcon
Modality: Small Molecules
Administration: Ophthalmic

Overview

Simbrinza is a fixed-dose combination ophthalmic suspension developed by Alcon for the reduction of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension. It combines brinzolamide, a carbonic anhydrase inhibitor, and brimonidine tartrate, an alpha-2 adrenergic receptor agonist. It is notable as the first fixed-dose combination therapy for glaucoma without a beta-blocker.

Brand names: Simbrinza
Other names: brinzolamide/brimonidine tartrate ophthalmic suspension

Targets

ADRA2A (α2A)CA2 (Carbonic Anhydrase 2)

Beyond the preview

Go deeper on Simbrinza.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simbrinza.

Explore the full profile